Skip to main content
SIU Annual Conference Main banner
 
Presentation Icons
Surgery Day
Surgery Day
Bench-to-Bedside
Bench-to-Bedside
SIU@U
SIU@U

    Debate: Immune checkpoint blockade plus BCG is the new standard first-line therapy for high-risk NMIBC

    Session: 7th B2B Uro-Oncology: GU Cancers Triad Meeting - BLADDER CANCER

    B2B-01: Debate: Immune Checkpoint Blockade Plus BCG Is the New Standard First-line Therapy for High-risk NMIBC

    Friday, October 31, 2025
    10:05 GMT+0

      Moderator(s)

    • Peter Black

      Professor
      University of British Columbia, Canada